Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - News - Pharmaceutical Development - November 19, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/19/18 - Amgen And Provention Bio to Develop Celiac Disease Treatment [Sport360]
On Nov. 5, 2018, Amgen and Provention Bio, a clinical-stage biopharmaceutical company focused on immune-mediated diseases, announced a licensing and co-development agreement for AMG 714, a novel anti-IL-15 monoclonal antibody, for the treatment of gluten-free diet non-responsive celiac disease. Under the terms of the agreement, Provention will cond
11/19/18 - Ascelia Pharma receives positive feedback from FDA on design of the pivotal Phase 3 study with Mangoral
Ascelia Pharma AB today announced that the company has successfully concluded discussions with the US Food and Drug Administration regarding the study design for the single pivotal Phase 3 trial for Mangoral as a contrast agent in patients with focal liver lesions and severe renal impairment. Ascelia Pharma will now complete the preparatory work
11/19/18 - ASIT biotech Launches Its Confirmatory Phase III Clinical Study with gp-ASIT+? in Grass Pollen Rhinitis Prevention Following the Investigator Meeting Hosted in Prague (Czech Republic) on November 16-17, 2018
ASIT biotech, a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, today announced that it hosted the investigator meeting in Prague on November 16-17, 2018 ahead of the launch of its confirmatory Phase III clinical study with gp-ASIT+? in grass pollen rhinitis prevention.
11/19/18 - Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that Herriot Tabuteau, MD, Axsome s Chief Executive Officer, will conduct investor meetings at the upcoming 2018 Global Mizuho Investor Conference on December 3, 2018.
11/19/18 - BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
BiondVax Pharmaceuticals Ltd., a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today issued a clarification regarding information published on November 13, 2018 in connection with the third quarter financial results. As correctly indicated in the financial tabl
11/19/18 - Brigham and Women's Hospital: Diabetes Drug Prevents Heart Failure
Brigham and Women's Hospital issued the following news release:. Results of the Dapagliflozin Effect on CardiovascuLAR Events- Thrombolysis in Myocardial Infarction 58 trial, sponsored by AstraZeneca, were presented by Stephen Wiviott, MD, a senior investigator in the TIMI Study Group and a cardiovascular medicine specialist at Brigham and Women's.
11/19/18 - CASI Pharmaceuticals | CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
-Acquired U.S. FDA- approved abbreviated new drug application from Laurus Labs Limited. ROCKVILLE, Md.- CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today r
11/19/18 - ContraFect to Present at Piper Jaffray Health Care Conference
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in a fireside chat at the Piper Ja
11/19/18 - CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China
CStone Pharmaceuticals today announced that a first patient has been enrolled and dosed in a Phase I clinical trial in China for the recombinant humanized anti-programmed death-1 monoclonal antibody CS1003. Frank Jiang, Chairman and CEO of CStone, "We are happy to see Phase I trial get under way in China. We plan to carry out global development f
11/19/18 - FDA Approves AEMCOLO? (Rifamycin), the First Antibiotic Approved for the Treatment of Travelers Diarrhea in Over a Decade
Dublin, Ireland- November 19, 2018- Cosmo Pharmaceuticals N.V. announced that the U.S. Food and Drug Administration has approved AEMCOLO?, containing 194 mg of Rifamycin as delayed-release tablets, a new minimally-absorbed antibiotic that is delivered to the colon, for treatment of Travelers' Diarrhea caused by non-invasive strains of Escherichia
11/19/18 - FDA approves antibacterial drug to treat travelers` diarrhea [Tehran Times (Iran)]
"Travelers` diarrhea affects millions of people each year and having treatment options for this condition can help reduce symptoms of the condition," said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA`s Center for Drug Evaluation and Research. The highest-risk destinations are in most of Asia as well as the M
11/19/18 - FDA Approves New Drug to Treat Travelers Diarrhea [Syrian Arab News Agency]
"Travelers` diarrhea affects millions of people each year and having treatment options for this condition can help reduce symptoms of the condition," said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDAs Center for Drug Evaluation and Research. The highest-risk destinations are in most of Asia as well as the Middle
11/19/18 - FDA approves treatment for peripheral T-cell lymphoma
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program... The post FDA approves treatment for peripheral T-cell lymphoma appeared first on European Pharmaceutical Review.
11/19/18 - Formosa Lab enters a new era of growth with Formosa Pharma, expanded CDMO service [T-break Tech (Middle East)]
These initiatives are all part of efforts to become a full-fledged integrated pharmaceutical company, says Dr Cheng Chen- yu, chairman and president of Formosa Lab. Through its biopharmaceutical subsidiary Formosa Pharmaceuticals, Formosa Lab ventured into new drug development, and is centred on the indications of ophthalmology, oncology,...
11/19/18 - Funding for new type of breast cancer treatment approach [Syrian Arab News Agency]
A husband-and-wife pair of researchers at the University of Virginia Cancer Center have been awarded funding for work to improve radiation therapy and breast surgery for patients with early-stage breast cancer. According to a release, radiation oncologist Timothy Showalter, MD, and breast cancer surgeon Shayna L. Showalter, MD, will use the $1.8 mi
11/19/18 - Gilead Sciences: China NMPA Approves Vemlidy For Chronic HBV Infection
FOSTER CITY- Gilead Sciences, Inc. announced that the China National Medical Products Administration has approved Vemlidy 25 mg, for chronic hepatitis B Virus Infection in adults and adolescents. Jinlin Hou, Nanfang Hospital of Southern Medical University. Vemlidy received marketing approval from the U.S. Food and Drug Administration and the Japane
11/19/18 - Global Clinical Chemistry Analyzer Market Comprehensive Study By 2018-2025 With Industry Players Like- Abbott, Danaher Corporation, Thermofisher Scientific, Roche, Johnson & Johnson, Siemens Healthine
Report Forecasting Regional and Global Analysis on Clinical Chemistry Analyzer Market By Product type (Consumables and Accessories (Reagents, Assay Kits, Microplates, Accessories), Instruments (Spectrophotometers, Flow Cytometers, Hematology Analyzers, Cell Counters), By End-User (Hospitals, Diagnostic Centers, Research Institutions, Pharmaceutical
11/19/18 - Imfinzi fails again in MYSTIC trial for first-line NSCLC
In another strike against tremelimumab, AstraZeneca plc said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the co-primary endpoint of improving overall survival in the Phase III MYSTIC trial to treat previously untreated non-small cell lung cancer. FDA has approved rival anti-PD-1 mAb Keytruda pembrolizumab from.
11/19/18 - IntraBio Receives Tay-Sachs and Sandhoff European Orphan Drug Designation
OXFORD, UK/ ACCESSWIRE/ November 19, 2018/ IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series for the treatment of GM2 Gangliosidosis, a rare lysosomal storag
11/19/18 - Liquid Handling Technology Market Size Worth $5.54 Billion By 2025: Grand View Research,Inc.
According to report published by Grand View Research, The global liquid handling technology market is expected to reach USD 5.54 billion by 2025. Major pharmaceutical and biopharmaceutical companies are rapidly integrating robotic solutions including automated liquid handling workstations to enhance their workflows, which in turn, is expected to...
11/19/18 - LMI070 Oral Candidate For SMA Type 1 Holds Promise, Preclinical Study Shows [Sport360]
LMI070, a candidate oral therapy under development by Novartis, is being tested in a Phase 1/ 2 clinical trial for infants with spinal muscular atrophy type 1.. A recent study describes how the compound was discovered from a large screen for SMN2 modulators in a nerve cell model, followed by several rounds of chemical optimization to increase poten
11/19/18 - New FDA-approved oral opioid draws mixed reactions at VCU New FDA-approved oral opioid draws mixed reactions at VCU
Amid the growing opioid crisis, the U.S. Food and Drug Administration has attracted criticism for approving a new kind of opioid that's five to 10 times more powerful than fentanyl, the deadliest drug in Virginia. Under the FDA' s approval guidelines, the drug, known as Dsuvia, can be distributed only by a health care professional in a certified me
11/19/18 - New opioid draws mixed responses New FDA-approved oral opioid draws mixed reactions at VCU
Amid the growing opioid crisis, the U.S. Food and Drug Administration has attracted criticism for approving a new kind of opioid that's five to 10 times more powerful than fentanyl, the deadliest drug in Virginia. Under the FDA's approval guidelines, the drug, known as Dsuvia, can be distributed only by a health care professional in a certified med
11/19/18 - Newly approved pill rapidly cures sleeping sickness [Sudan Tribune]
The European Medicines Agency on Friday approved use of fexinidazole shown to be effective in treating all stages of sleeping sickness. This approval is a result of clinical trials led by the Drugs for Neglected Diseases Initiative, a non-profit research and development organisation, and an application submitted by Sanofi, a global biopharmaceutica
11/19/18 - Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals, Inc., a leading U.S.- based multi-platform gene therapy company, today announces the clearance of the Company s Investigational New Drug application by the U.S. Food and Drug Administration for RP-L201. We are excited to achieve this important milestone ahead of schedule, and look forward to working with the medical and p
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415